Actavis’ leadership has focused on launching generic drugs for patients with rare conditions – the pharmaceutical version of a niche market. Jim Cramer and Action Alerts PLUS Research Director Jack Mohr discuss why Actavis is severely undervalued and an extremely compelling healthcare investment at these levels. The company is not only a serial acquirer; it purchases great companies and makes them even better, through disciplined cost management, synergy realization and pipeline expansion. Its recent acquisition of Allergan is a true game changer, as it offers Actavis high-profile brands including Botox, Restasis and Namanda. The most exciting of these is Botox, which currently contributes $2 billion in annual sales.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
